Timonacic's chemical name, L-Syrosin-4, is a new anti-tumor drug that converts cancer cells into normal cells. Experimental studies have shown that Timonacic can increase cAMP concentration by adenosine cyclase of cells.
The anticancer effect of timonacic is thought to be broken down hemi-glycine and formaldehyde in the body. Semi-glycine as a carrier has a certain affinity for tumor tissues, and the aldehyde moiety acts on the nucleophilic portion of the nucleic acid or protein of the tumor cells. Timonacic can rebuild damaged microfilaments and microtubule systems in cancer cells, restore the function of cell surface and nuclear nucleus transmission signals in normal cells, and finally normalize cells to achieve anti-cancer effects.
Timonacic can reverse the transformation of tissue cultured tumor cells, bringing the morphology close to normal cells, and restoring the structure and function of the plasma membrane. In particular, the lost contact inhibition function is restored, while growth and proliferation are inhibited. In contact with Timonacic-treated Hela cells, contact inhibition was restored. Timonacic has a prominent anti-tumor effect for head and neck squamous cell carcinoma, and has a positive effect on squamous cell carcinoma and other solid tumors in other areas, such as breast cancer, kidney cancer, ovarian tumor, thyroid pain and knee cancer. However, oral administration does not appear to have antitumor activity. Timonacic also has a protective effect on the liver.
Pharmacokinetics and metabolism
As revealed by rats experiments, Timonacic is quickly taken from the stomach into the intestines after oral administration and is quickly absorbed in the intestines. Timonacic appears to be absorbed by the active transport mechanism. After oral administration, thiaproline is metabolized to cysteine and formaldehyde in the liver, and formaldehyde is oxidized to formic acid, which is then converted into carbon dioxide and water to detoxify. Vitro studies on the metabolism of thioproline in rat liver homogenate revealed the formation of carbamoylcysteine. After oral administration, the main metabolites measured in urine were taurine, alanine and glycine, the same as after administration of cysteine hydrochloride. However, after intravenous administration, the drug discharged from the urine was not metabolized.